Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy

被引:3
|
作者
Huang, Chih-Wen [1 ]
Yang, Chen-Ta [1 ]
Su, Pei-Yuan [1 ,2 ]
Chen, Yang-Yuan [1 ,2 ]
Huang, Siou-Ping [1 ]
Yen, Hsu-Heng [1 ,2 ]
机构
[1] Changhua Christian Hosp, Dept Internal Med, Div Gastroenterol, Changhua 500, Taiwan
[2] Natl Chung Hsing Univ, Coll Med, Taichung 400, Taiwan
关键词
chronic hepatitis B; entecavir; tenofovir alafenamide; finite therapy; clinical relapse; HBEAG-NEGATIVE PATIENTS; DISOPROXIL FUMARATE; SURFACE-ANTIGEN; SAFETY;
D O I
10.3390/biomedicines11030752
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chronic hepatitis B (CHB) relapse occurs after the cessation of nucleos(t)ide analogues (NUC) therapy due to the waning of viral suppression. Few studies have investigated the viral relapse rate and clinical relapse rate after tenofovir alafenamide (TAF) therapy. We compared the CHB relapse rate between TAF and entecavir therapy. We enrolled patients with chronic hepatitis B who underwent TAF or entecavir therapy. NUC therapy was terminated after HBeAg loss for 1 year in HBeAg-positive patients and after undetectable serum HBV DNA on three separate tests each >6 months apart in HBeAg-negative patients. After cessation of NUC therapy, we followed alanine aminotransferase (ALT) levels at 12, 24, and 48 weeks. Serum HBV DNA levels were checked if patients showed a two-fold elevation from the upper limit of normal ALT levels (41 IU/mL). Clinical relapse (CR) was defined as a two-fold elevation in ALT levels and HBV DNA levels > 2000 IU/mL. We then investigated the CR rate of HBV after cessation of TAF and entecavir therapy at 12, 24, and 48 weeks. Of the 117 patients enrolled, 78 were in the entecavir group and 39 were in the TAF group. At 12 weeks after cessation of NUC therapy, no patients had HBV CR in the entecavir group. However, three patients (CR cumulative rate 7.9%) had CR in the TAF group. At 24 weeks, the CR cumulative rate in the entecavir and TAF groups were 1.3% and 13.2%, respectively (p < 0.05). At 48 weeks, the CR cumulative rates were 9.2% and 24.2%, respectively (p = 0.055). Patients in the TAF group had a higher cumulative rate of CR than those in the entecavir group (log-rank p = 0.023). Furthermore, patients in the TAF group had earlier CR times than those in the entecavir group, especially in the first 24 weeks after cessation of therapies (p < 0.05). The cessation of TAF therapy had significantly earlier and higher CR rates than that of entecavir therapy. Close monitoring of liver function and HBV DNA levels may be necessary, especially within 24 weeks after cessation of TAF therapy.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy
    Chiu, Shao-Ming
    Kuo, Yuan-Hung
    Wang, Jing-Houng
    Hung, Chao-Hung
    Hu, Tsung-Hui
    Lu, Sheng-Nan
    Chen, Chien-Hung
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (13) : 2989 - +
  • [22] COMPARABLE RISK OF RENAL DYSFUNCTION BETWEEN ENTECAVIR AND TENOFOVIR ALAFENAMIDE IN PATIENTS WITH CHRONIC HEPATITIS B
    Yang, Jiwon
    Lee, Yeojin
    Hong, Hyeyeon
    Chung, Sung Won
    Cho, Minjoo
    Choi, Won-Mook
    Lee, Danbi
    Shim, Ju Hyun
    Kim, Kang Mo
    Lim, Young-Suk
    Lee, Han Chu
    Choi, Jonggi
    HEPATOLOGY, 2023, 78 : S510 - S510
  • [23] Observational pilot study of switching from entecavir to tenofovir alafenamide in patients with chronic hepatitis B
    Matsubara, Takuya
    Hagiwara, Satoru
    Nishida, Naoshi
    Omaru, Naoya
    Yoshida, Akihiro
    Yamamoto, Tomoki
    Komeda, Yoriaki
    Takenaka, Mamoru
    Kudo, Masatoshi
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [24] Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir
    Yuan, Gui-Cai
    Chen, Ai-Zhen
    Wang, Wei-Xin
    Yi, Xu-Lan
    Tu, Long
    Peng, Fang
    Qiu, Zhi-Hong
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (34) : 8139 - 8146
  • [25] Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Ito, Takanori
    Tanaka, Junko
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 : E898 - E904
  • [26] Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy
    Su, Tung-Hung
    Yang, Hung-Chih
    Tseng, Tai-Chung
    Liou, Jyh-Ming
    Liu, Chen-Hua
    Chen, Chi-Ling
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Liu, Chun-Jen
    Kao, Jia-Horng
    JOURNAL OF INFECTIOUS DISEASES, 2018, 217 (08): : 1193 - 1201
  • [27] Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
    Ishido, Shun
    Tamaki, Nobuharu
    Uchihara, Naoki
    Suzuki, Keito
    Tanaka, Yuki
    Miyamoto, Haruka
    Yamada, Michiko
    Matsumoto, Hiroaki
    Nobusawa, Tsubasa
    Keitoku, Taisei
    Takaura, Kenta
    Tanaka, Shohei
    Maeyashiki, Chiaki
    Yasui, Yutaka
    Takahashi, Yuka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Itakura, Jun
    Kurosaki, Masayuki
    Izumi, Namiki
    JGH OPEN, 2023, 7 (08): : 567 - 571
  • [28] Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B
    Kumada, Takashi
    Toyoda, Hidenori
    Yasuda, Satoshi
    Ito, Takanori
    Tanaka, Junko
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (1S) : E898 - E904
  • [29] Tenofovir Alafenamide: A Review in Chronic Hepatitis B
    Lesley J. Scott
    Henry L. Y. Chan
    Drugs, 2017, 77 : 1017 - 1028
  • [30] Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B
    Choi, Hannah S. J.
    Hirode, Grishma
    Chen, Chien-Hung
    Su, Tung-Hung
    Seto, Wai-Kay
    Van Hees, Stijn
    Papatheodoridi, Margarita
    Lens, Sabela
    Wong, Grace L. H.
    Brakenhoff, Sylvia M.
    Chien, Rong-Nan
    Feld, Jordan J.
    Sonneveld, Milan J.
    Chan, Henry L. Y.
    Forns, Xavier
    Papatheodoridis, George, V
    Vanwolleghem, Thomas
    Yuen, Man-Fung
    Hsu, Yao-Chun
    Kao, Jia-Horn
    Cornberg, Markus
    Hansen, Bettina E.
    Jeng, Wen-Jue
    Janssen, Harry L. A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (06) : 1513 - 1522